
TABLE OF CONTENTS

Contents.....	i-x
List of Tables.....	xi-xii
List of Figures.....	xiii-xvi
List of Abbreviations.....	xvii-xxi
1. ABSTRACT.....	1
2. INTRODUCTION	2
3. REVIEW OF LITERATURE	11
3.1. Calcium.....	11
3.2. SOCE: Historical Development of the Concept	11
3.3. The Physiological Function of SOC Channels	13
3.4. Structural insights into calcium sensing by Stromal interaction molecules	14
3.5. Stromal Interaction Molecule Domain Organization.....	14
3.6. Identification of Orai.....	16
3.7. Channel Gating and Inactivation	16
3.8. Essential Structures within STIM1 that Mediate Interaction with and Activation of Orai	17
3.9. Structures Within Orai that Mediate Interaction with STIM1	18
3.10. Conformational Rearrangement of STIM1 Accompanies Orai1 Activation	19
3.11. Gating of Orai Channels	20
3.12. Fast Inactivation of Orai Channels by a STIM1 Domain	21
3.13. STIM1, Communicating the Depleted State of the ER to the PM.....	21
3.14. SERCA, Refilling the ER	23
3.15. Adenylyl Cyclase, SOCE Downstream	23
3.16. STIM1/Orai1-Mediated Store-operated Ca^{2+} Entry in Cardiovascular Disease ..	24
3.17. SOCE and STIM1/Orai1 Proteins.....	24
3.18. STIM/Orai1 Proteins and Cardiovascular Diseases.....	25
3.18.1. Thrombosis	25
3.18.2. Atherosclerosis.....	25
3.18.3. Hypertension	26
3.18.4. Cardiac Hypertrophy.....	26

4. PLANT PROFILE	28
4.1. Piper betle	28
4.2. Rubia Cordifolia.....	31
5. MATERIAL AND METHODS	34
5.1. Material	34
5.1.1. Drugs:.....	34
5.1.2. Chemicals:.....	34
5.1.3. Plasma:	35
5.1.4. Cell line:.....	35
5.1.5. Antibodies:	35
5.1.6. Kits:.....	36
5.1.7. Animals:	36
5.2. Methods.....	37
5.2.1. Prepration and Evaluation of extracts of Piperbetle and Rubia cordifolia.....	37
5.2.1.1. Preparation of Plant Extract	37
5.2.1.2. Proximate analysis	37
5.2.1.3. Analysis of Phytoconstituents.....	38
5.2.1.4. Evaluating antioxidant activity of PBEA and RCHA: In-vitro	43
5.2.1.4.1. DPPH radical scavenging assay.....	43
5.2.1.4.2. β -carotene bleaching assay	44
5.2.1.4.3. Superoxide anion radical scavenging activity.....	44
5.2.1.4.4. Hydroxyl redical scavenging activity	45
5.2.1.4.5. Hydrogen peroxide scavenging activity.....	46
5.2.1.4.6. Reducing power method	47
5.2.2. Pharmacokinetic Study of 2-APB.....	48
5.2.2.1. Development of RP-HPLC method of 2-APB.....	48
5.2.2.1.1. Method validation	49
5.2.2.1.2. Bioanalytical method of 2-APB in Human plasma.....	50
5.2.2.1.3. Method validation	50
5.2.2.1.4. Pharmaco-kinetic study of 2-APB	51
5.2.3.1. Cell-viability assay.....	51

5.2.3.1.1. MTT assay for cell viability.....	54
5.2.3.2. Intracellular reactive oxygen species (ROS) levels assay.....	55
5.2.3.3. Cellular antioxidant enzyme profile.....	55
5.2.3.4. Annexin-FITC apoptosis assay	56
5.2.3.5. Reagents:.....	56
5.2.3.6. Vascular reactivity assay (Calcium channel blocking action on aorta) ...	57
5.2.4. Pharmacological evaluation of 2-APB, eugenol, PBEA and RCHA in selective cardiovascular disorders.....	58
5.2.4.1. Angiotension-II induced Acute hypertension in vagotomized rats.....	58
5.2.4.1.1. Measurement of Blood pressure	59
5.2.4.1.2. Assay of Calcium.....	60
5.2.4.1.3. Assay of Sodium.....	60
5.2.4.1.4. Assay of Magnesium.....	61
5.2.4.1.5. Assay of Lipid Peroxidation (Malonedialdehyde [MDA] content) 62	
5.2.4.1.6. Assay of Superoxide Dismutase (SOD)	63
5.2.4.1.7. Assay of Catalase (CAT)	64
5.2.4.1.8. Assay of Reduced Glutathione (GSH).....	65
5.2.4.1.9. Measurement of STIM1 and Orai1 protein expression in heart, kidney and aorta by Western blot analysis	65
5.2.4.2. Isoproterenol induced global ischemia	68
5.2.4.2.1. Blood pressure measurement by non-invasive method (Tail cuff method)	70
5.2.4.2.2. Electrocardiography	71
5.2.4.2.3. Hemodynamic parameter	71
5.2.4.2.4. Gravimetric Analysis.....	72
5.2.4.2.5. Assay of Creatine Kinase-MB (CK-MB).....	72
5.2.4.2.6. Assay of Lactate Dehydrogenase (LDH).....	73
5.2.4.2.7. Assay of Calcium.....	73
5.2.4.2.8. Assay of Potassium.....	73
5.2.4.2.9. Assay of sodium	74
5.2.4.2.10. Assay of Tumor Necrosis Factor – Alpha (TNF- α)	74

5.2.4.2.11. Assay of Interlukin-6 (IL-6)	76
5.2.4.2.12. Assay of Lipid Peroxidation (Malonedialdehyde [MDA])	77
5.2.4.2.13. Assay of Superoxide Dismutase (SOD)	77
5.2.4.2.14. Assay of Catalase (CAT)	77
5.2.4.2.15. Assay of Reduced Glutathione (GSH)	77
5.2.4.2.16. Assay of Glutathione Peroxidase (GPx).....	78
5.2.4.2.17. Assay of Glutathione S-Transferase (GST).....	79
5.2.4.2.18. Sodium-Potassium Dependent Adenosin Triphosphatase (Na ⁺ K ⁺ ATPase).....	79
5.2.4.2.19. Calcium Dependent Adenosine Triphosphatase (Ca ²⁺ ATPase) ..	81
5.2.4.2.20. Magnesium Dependent Adenosine Triphosphatase (Mg ²⁺ ATPase)	81
5.2.4.2.21. Determination of Inorganic Phosphorus (P _i):	82
5.2.4.2.22. Estimation of Tissue Total Proteins	83
5.2.4.2.23. Measurement of Heart Tissue Nitrite Level	84
5.2.4.2.24. Measurement of Myeloperoxidase (MPO) activity.....	84
5.2.4.2.25. Determination of infarct Size (Macroscopic enzyme mapping)...	85
5.2.4.2.26. Histopathology study	86
5.2.4.2.27. Measurement of STIM1 and Orai1 protein expression in heart by Western blotting.....	86
5.2.4.3. Coronary artery ligation induced Reperfusion injury	86
5.2.4.3.1. Assay of CK-MB	88
5.2.4.3.2. Measurement of STIM1 and Orai1 protein expression in heart by western blot analysis	88
5.2.5. Safety study of drug	88
5.2.5.1. Cellular Toxicity	88
5.2.5.2. Doxorubicin induced Cardiotoxicity.....	88
5.2.5.2.1. Assay of Lactate Dehydrogenase (LDH).....	90
5.2.5.2.2. Measurement of STIM1 and Orai1 protein expression in heart by Western blotting.....	90
5.2.5.3. Acute Toxicity Study OECD 423	90
5.2.5.4. Acute Toxicity Study OECD 407	91

5.2.5.4.1. Assay of Total Cholesterol.....	92
5.2.5.4.2. Assay of Total Billirubin	92
5.2.5.4.3. Assay of Alanine Aminotransferase (ALT).....	93
5.2.5.4.4. Assay of Aspartate aminotransferase (AST).....	93
5.2.5.4.5. Assay of Creatinine.....	94
5.2.5.4.6. Assay of Total Protein	94
5.2.5.4.7. Assay of Albumin	95
5.2.5.4.8. Assay of Globulin	95
5.2.5.4.9. Assay of Blood Urea Nitrogen.....	95
5.2.5.4.10. Assay of Sodium	96
5.2.5.4.11. Assay of Potassium	96
5.2.5.4.12. Assay of Calcium	96
5.2.5.4.13. Necropsy and Organ Body weight.....	96
5.2.5.4.14. Histopathology	97
5.3. Statistical analysis.....	97
6. RESULTS	98
6.1 Authentification of <i>Piper betle</i> and <i>Rubia cordifolia</i> powder	98
6.2 Prepration and evaluation of extract of <i>Piper betle</i> and <i>Rubia cordifolia</i>	99
6.2.1 Extarction yield.....	99
6.2.2 Proximate analysis	99
6.2.3 Phytochemical screening test.....	100
6.2.4 Total Phenolics content.....	102
6.2.5 Total Flavonoids content.....	103
6.2.6 Quanitative determination of Eugenol by GC-FID.....	103
6.2.7 Quanitative determination of Eugenol by HPTLC	106
6.2.8 Antioxidant activity of PBEA and RCHA: In-vitro.....	109
6.2.8.1 DPPH Assay.....	110
6.2.8.2 β -carotenebleaching assay	110
6.2.8.3 Superoxide anion radicals scavenging assay	111
6.2.8.4 Hydroxyl radical scavenging assay.....	112
6.2.8.5 Hydrogen peroxide scavenging activity.....	112

6.2.8.6 Reducing Power assay	113
6.3 Evaluation of 2-APB and Eugenol.....	114
6.3.1 IR spectra of 2-aminoethyl diphenyl borinate (2-APB).....	114
6.3.2 Selection of Detection Wavelength by UV	114
6.3.3 Optimization of mobile phase	115
6.3.4 Method validation of 2-APB.....	116
6.3.4.1 Linearity and Range.....	116
6.3.4.2 Precision.....	117
6.3.4.3 Sensitivity	117
6.3.4.4 Accuracy	118
6.3.4.5 System suitability	118
6.3.5 Bioanalytical method of 2-APB.....	118
6.3.5.1 Method validation of bioanalytical method	119
6.3.5.1.1 Linearity and Range.....	119
6.3.5.1.2 System Suitability	120
6.3.5.1.3 Precision.....	120
6.3.5.1.4 Selectivity	120
6.3.5.1.5 Recovery	121
6.3.6 Pharmacokinetic study.....	121
6.3.7 IR spectra of Eugenol.....	123
6.4 In-vitro safety and efficacy study of 2-APB, Eugenol, PBEA and RCHA through cellular model.	123
6.4.1 Cellular studies.....	123
6.4.1.1 MTT assay	123
6.4.1.2 Intra cellular ROS	126
6.4.1.3 Cellular antioxidants	127
6.4.1.4 Apoptosis assay.....	128
6.4.1.5 Vascular reactivity assay.....	129
6.5 Pharmacological evaluation of 2-APB, Eugenol, PBEA and RCHA in selected cardiovascular disorders through in-vivo study.	131
6.5.1 Angiotensin-II induced acute hypertension in rats.	131

6.5.1.1 Effect of drugs on systolic blood pressure in Ag-II induced acute hypertension in rats.....	131
6.5.1.2 Effect of drugs on diastolic blood pressure in Ag-II induced acute hypertension in rats.....	131
6.5.1.3 Effect of drugs on calcium level at different time point in Ag-II induced acute hypertension in rats.	132
6.5.1.4 Effect of drugs on sodium level in Ag-II induced acute hypertension in rats.....	133
6.5.1.5 Effect of drugs on magnesium level in Ag-II induced acute hypertension in rats.	134
6.5.1.6 Effect of drugs on heart and kidney malondialdehyde level in Ag-II induced acute hypertension in rats.	135
6.5.1.7 Effect of drugs on heart and kidney superoxide dismutase level in Ag-II induced acute hypertension in rats.	136
6.5.1.8 Effect of drugs on heart and kidney catalase level in Ag-II induced acute hypertension in rats.....	137
6.5.1.9 Effect of drugs on heart and kidney glutathione level in Ag-II induced acute hypertension in rats.	138
6.5.1.10 Effect of drugs on STIM1 and Orai1 in Ag-II induced acute hypertension in rats.	139
6.5.2 Isoproterenol induced global ischemia.	145
6.5.2.1 Pilot studies.....	145
6.5.2.1.1 Effect of PBEA and RCHA on CK-MB in ISO induced global ischemia in rats.	145
6.5.2.1.2 Effect of PBEA and RCHA on LDH in ISO induced global ischemia in rats.	145
6.5.2.1.3 Effect of PBEA and RCHA on malondialdehyde in ISO induced global ischemia in rats.	146
6.5.2.1.4 Effect of PBEA and RCHA on glutathione in ISO induced global ischemia in rats.	147
6.5.2.2 Drug efficacy Study	148

6.5.2.3 Main studies	149
6.5.2.3.1 Effect of drugs on blood pressure in ISO induced global ischemia in rats.	149
6.5.2.3.2 Effect of drugs on electrocardiography in ISO induced global ischemia in rats.	150
6.5.2.3.3 Effect of drugs on hemodynamic parameters in ISO induced global ischemia in rats.	154
6.5.2.3.4 Effect of drugs on heart weight to body weight ratio in ISO induced global ischemia in rats.	155
6.5.2.3.5 Effect of drugs on CK-MB in ISO induced global ischemia in rats.	156
6.5.2.3.6 Effect of drugs on LDH in ISO induced global ischemia in rats.	157
6.5.2.3.7 Effect of drugs on serum calcium in ISO induced global ischemia in rats.	157
6.5.2.3.8 Effect of drugs on heart calcium in ISO induced global ischemia in rats.	158
6.5.2.3.9 Effect of drugs on potassium in ISO induced global ischemia in rats.	159
6.5.2.3.10 Effect of drugs on sodium in ISO induced global ischemia in rats.	159
6.5.2.3.11 Effect of drugs on TNF- α in ISO induced global ischemia in rats.	160
6.5.2.3.12 Effect of drugs on IL-6 in ISO induced global ischemia in rats.	161
6.5.2.3.13 Effect of drugs on antioxidant enzymes in ISO induced global ischemia in rats.	161
6.5.2.3.14 Effect of drugs on Na ⁺ /K ⁺ ATPase in ISO induced global ischemia in rats.	164
6.5.2.3.15 Effect of drugs on Ca ⁺⁺ ATPase in ISO induced global ischemia in rats.	164
6.5.2.3.16 Effect of drugs on Mg ⁺⁺ ATPase in ISO induced global ischemia in rats.	165
6.5.2.3.17 Effect of drugs on nitrite in ISO induced global ischemia in rats.	166
6.5.2.3.18 Effect of drugs on MPO in ISO induced global ischemia in rats.	166
6.5.2.3.19 Effect of drugs on infracts size in ISO induced global ischemia	

in rats.....	167
6.5.2.3.20 Effect of drugs on histopathology in ISO induced global ischemia in rats.....	169
6.5.2.3.21 Effect of drugs on STIM1 and Orai1 expression in ISO induced global ischemia in rats.....	171
6.5.3 Coronary artery ligation induced reperfusion injury.	173
6.5.3.1 Effect of drugs on CK-MB in LAD induced reperfusion injury in rats...173	
6.5.3.2 Effect of drugs on STIM1 and Orai1 in LAD induced reperfusion injury in rats.....	173
6.6 Saftey study of drugs	175
6.6.1 Cellular toxicity of drugs	175
6.6.2 Doxorubicin induced Cardiotoxicity.....	176
6.6.2.1 Effect of drugs on lactate dehydrogenase in DOXO induced cardio toxicity in rats.	176
6.6.2.2 Effect of drugs on STIM1 and Orai1 in DOXO induced cardio toxicity in rats.....	177
6.6.3 Acute toxicity study of PBEA and RCHA by OECD 423	179
6.6.4 Sub-acute toxicity study of PBEA by OECD 407	180
7. DISCUSSION	191
8. SUMMARY AND CONCLUSION	210
8.1. Aim of the study.....	210
8.2. Work Plan	211
8.3. Phytochemical screening and Standardization of PBEA and RCHA	212
8.4. Development of RP-HPLC method and Pharmacokinetic study.....	212
8.5. In-Vitro cell line study of selected drugs.....	212
8.6. In-vivo activity of Selected drugs	213
8.7. Safety of Selected drugs.....	215
9. BIBLIOGRAPHY	216
10. PUBLICATION AND PRESENTATION	243
10.1. Paper Publication	243
10.2. Achievement	243

10.3. Lecture delivered	243
10.4. Conferences, seminars, workshops, symposium attended	243
11. ANNEXURE.....	245